NCT03244280已完成1 期
A Study of the Systemic Absorption of Once Daily MOB015B When Applied for 28 Days in Subjects With Moderate to Severe Onychomycosis of the Toenails.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- To measure the Cmax
研究概览
简要总结
A Study of the Systemic Absorption of Once Daily MOB015B when Applied for 28 Days in Subjects with Moderate to Severe Onychomycosis of the Toenails.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 70 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects who understand the study procedures and agree to participate by providing written informed consent. Subject must be willing to authorize use and disclosure of protected health information collected for the study.
- •Male or female subjects 12 to 70 years of age (inclusive), at the time of consent.
- •Subject has a body mass index (BMI) from ≥ 18.5 to ≤ 35.0 (kg/m2), at the screening visit.
- •Females of childbearing potential must be using contraception during the study which can include abstinence or hormonal contraceptives. All women of childbearing potential must be willing to complete a urine pregnancy test on Days 1, 14, and
- •Subjects must present with a clinical diagnosis of moderate to severe subungal onychomycosis with at least 50% involvement of both great toenails. In addition, 4 other toenails must be affected.
- •Subjects must have a positive KOH microscopy for at least 1 great toenail at the screening visit.
- •Subjects must be willing to complete clinical laboratory testing.
- •Subjects must be willing to undergo alcohol and drug (e.g., benzodiazepines, cocaine, opioids, cannabinoids, and barbiturates) tests at the Day 1 visit.
- •Subjects must be willing to remain at the study site for approximately 11 hours and undergo multiple blood draws on Day 1 and
- •Subjects must be able to reach their toes to apply study drug or have a caregiver willing to help apply the study drug on a daily basis as directed.
排除标准
- •Female subjects who are pregnant, nursing/breastfeeding, or plan to become pregnant within the study period.
- •Subjects with chronic or active liver disease, renal impairment, cutaneous or systematic lupus erythematosus, or any other disease or medical condition that in the opinion of the investigator would interfere with the study or place the subject at undue risk.
- •Subject with hypersensitivity to terbinafine or the vehicle excipients.
- •Subjects who have been treated with systematic formulations of terbinafine in the 12 months prior to the Day 1 visit.
- •Subjects who have been treated with topical formulations of terbinafine in the 6 months prior to the day 1 visit.
- •Subjects who take or have taken systematic medication that may interfere with the study or place the subject at undue risk in the 30 days before the day 1 visit (e.g., rifampin, cimetidine, phenobarbital, phenytoin, carbamazepine, terfenadine or digoxin).
- •Subjects who take or have taken systemic medication in the 30 days before the Day 1 visit that interferes with the terbinafine plasma assay.
- •Subjects who have consumed grapefruit products during the 30 days prior to the Day 1 visit.
- •Subjects who are not willing to refrain from caffeinated beverage consumption on Day 1 and
- •Subjects with a current history of consumption of more than three alcoholic drinks per day or consumption of alcohol within 48 hours prior to Day 1 visit (one drink is equal to one unit of alcohol, one glass of wine, half pint of beer or one ounce of spirits).
- •Subjects with an ongoing or recent history of treatment for substance abuse.
- •Subjects who have participated in a study of an investigational drug 60 days prior to the Day 1 visit.
- •Subjects with a history of multiple syncopal episodes.
- •Subjects with positive tests for drugs or alcohol at Day 1 visit.
- •Subjects who are unable to comply with study requirements.
- •Subjects who are not willing to abstain from all toenail treatments such as toenail polish, pedicures and/or foot soaks (including nail clipping or debridement), for 3 days prior to Day 1 visit and during the study.
- •Donation of blood (one unit or 350 mL) within 90 days prior to Day 1 visit.
研究组 & 干预措施
MOB015B
Other
干预措施: MOB015B (Drug)
结局指标
主要结局
To measure the Cmax
时间窗: 28 days
To measure the Cmax after 1 day and 28 days
to measure AUC0-t
时间窗: 28 days
To measure AUC0-t after 1 day and 28 days
To measure the Tmax
时间窗: 28 days
To measure Tmax after 1 day and 28 days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed ConditionHealthyNCT00939835Torrent Pharmaceuticals Limited
已完成
1 期
Levetiracetam 1000 mg Under Non-Fasting ConditionsHealthyNCT00859430Teva Pharmaceuticals USA22
已完成
1 期
Multiple Dose BE Study With Nevirapine 400mg PR TabletsHIV-1NCT02202005Ratiopharm GmbH46
已完成
1 期
Levetiracetam 1000 mg Under Fasting ConditionsHealthyNCT00859521Teva Pharmaceuticals USA30
已完成
1 期
A Study of Two Different Test Formulations Compared to the Reference Formulation of Macitentan in Healthy Adult ParticipantsHealthyNCT05392530Actelion23